Zhdan V. M., Tkachenko M. V., Babanina M. Yu., Volchenko H. V., Kitura Ye. M., Kyrian O. A., Ivanytskyі I. V., Lebid V. G.

PREVALENCE AND STRUCTURE OF RISK FACTORS FOR CORONARY ARTERY DISEASE IN PATIENTS WITH GOUTY ARTHRITIS

---

Show/Download

About the author:

Zhdan V. M., Tkachenko M. V., Babanina M. Yu., Volchenko H. V., Kitura Ye. M., Kyrian O. A., Ivanytskyі I. V., Lebid V. G.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

Gout is one of the most common forms of chronic inflammatory arthritis and is characterized not only by joint involvement but also by significant comorbidity, particularly cardiovascular disease. Population-based studies indi cate a higher prevalence of coronary heart disease (CHD) in patients with gout compared to the general population; however, the role of traditional and specific risk factors in the development of cardiovascular risk remains poorly understood. The aim was to assess the prevalence of CHD among men with gout residing in the city of Poltava and Poltava Region, and to analyze the pattern of traditional cardiovascular risk factors and clinical characteristics of gout asso ciated with the development of CHD. The retrospective study included 82 men with a verified diagnosis of gout, who were divided into two groups based on the presence of CHD. Clinical manifestations of gout, laboratory parameters, the structure of comorbid conditions, and traditional risk factors for cardiovascular disease were analyzed. CHD was detected in 40% of patients, with one-third of them having a history of myocardial infarction. The devel opment of CHD was significantly associated with a duration of gout exceeding 10 years, involvement of more than five joints, the presence of intraosseous tophi, nephrolithiasis, and chronic kidney disease. Among traditional risk factors, abdominal obesity, hypertension, and elevated levels of total cholesterol and creatinine were significant. At the same time, no direct link was established between serum uric acid levels and the risk of CHD. The severity of gout and the high prevalence of traditional cardiovascular risk factors play a key role in the devel opment of CHD in patients with gout. Additional adverse factors include low adherence to urate-lowering therapy and frequent use of nonsteroidal anti-inflammatory drugs. The results obtained support the need for a multidisci plinary, personalized approach to the management of patients with gout, including active identification and correc tion of cardiovascular risk factors and timely prevention of CHD complication.

Tags:

Bibliography:

1. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380-390. DOI: 10.1038/s41584-020-0441-1.
2. Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: Case-control study. Ann Rheum Dis. 2016;75(1):210-217. DOI: 10.1136/annrheumdis-2014-206410.
3. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: An update on prevalence and treatment options. BMC Med. 2017;15(1):123. DOI: 10.1186/s12916-017-0890-9.
4. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894-900. DOI: 10.1161/CIRCULATIONAHA.107.703389.
5. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688-2696. DOI: 10.1002/art.22014.
6. De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK. Independent impact of gout on the risk of acute myocardial infarction among elderly women: A population-based study. Ann Rheum Dis. 2010;69(6):1162-1164. DOI: 10.1136/ard.2009.122770.
7. Sanchez-Lozada LG, Rodriguez-Iturbe B, Kelley EE, Nakagawa T, Madero M, Feig DI, et al. Uric acid and hypertension: An update with recommendations. Am J Hypertens. 2020;33(7):583-594. DOI: 10.1093/ajh/ hpaa044.
8. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282(6):F991-F997. DOI: 10.1152/ajprenal.00283.2001.
9. Park JJ, Roudier MP, Soman D, Mokadam NA, Simkin PA. Prevalence of birefringent crystals in cardiac and prostatic tissues: An observational study. BMJ Open. 2014;4(7):e005308. DOI: 10.1136/bmjopen-2014-005308.
10. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. DOI: 10.1136/annrheumdis-2016-209707.
11. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. DOI: 10.1093/eurheartj/ehy339.
12. Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-779. DOI: 10.1136/annrheumdis-2021-221733.
13. Liu SC, Xia L, Zhang J, Lu XH, Hu DK, Zhang HT, et al. Gout and risk of myocardial infarction: A systematic review and meta-analysis of cohort studies. PLoS One. 2015;10(7):e0134088. DOI: 10.1371/journal.pone. 0134088.
14. Huang KH, Tai CJ, Tsai YF, Kuan YH, Lee CY. Correlation between gout and coronary heart disease in Taiwan: A nationwide population based cohort study. Acta Cardiol Sin. 2019;35(6):634-640. DOI: 10.6515/ACS.201911 _35(6).20190403B.
15. Liang L, Hou X, Bainey KR, Zhang Y, Tymchak W, Qi Z, et al. The association between hyperuricemia and coronary artery calcification development: A systematic review and meta-analysis. Clin Cardiol. 2019;42(11):1079-1086. DOI: 10.1002/clc.23266.
16. Wijnands JM, Boonen A, Dagnelie PC, van Greevenbroek MM, van der Kallen CJ, Ferreira I, et al. The cross-sectional association between uric acid and atherosclerosis and the role of low-grade inflammation: The CODAM study. Rheumatology (Oxford). 2014;53(11):2053-2062. DOI: 10.1093/ rheumatology/keu239.
17. Essex MN, Hopps M, Bienen EJ, Udall M, Mardekian J, Makinson GT. Evaluation of the relationship between serum uric acid levels and cardiovascular events in patients with gout: A retrospective analysis using electronic medical record data. J Clin Rheumatol. 2017;23(3):160 166. DOI: 10.1097/RHU.0000000000000496.
18. Wu J, Lei G, Wang X, Tang Y, Cheng H, Jian G, et al. Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities. Oncotarget. 2017;8(46):80688-80699. DOI: 10.18632/ oncotarget.21079.
19. Zhdan VM, Kitura OIe, Kitura YeM, Babanina MIu, Tkachenko MV. Hiperurykemiia i arterialna hipertenziia u zahalnolikarskii praktytsi. Simeina medytsyna. 2015;4(60):48-50. [in Ukrainian].
20. Schjerning A-M, McGettigan P, Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol. 2020;17(9):574 584. DOI: 10.1038/s41569-020-0366-z.
21. Yang Y, Xian W, Wu D, Huo Z, Hong S, Li Y, et al. The role of obesity, type 2 diabetes, and metabolic factors in gout: A Mendelian randomization study. Front Endocrinol (Lausanne). 2022;13:917056. DOI: 10.3389/fendo. 2022.917056.
22. Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: Meta-analysis of observational studies. Arthritis Res Ther. 2015;17(1):90. DOI: 10.1186/s13075-015-0610-9.
23. Tkachenko MV. Hipourykemichna terapiia dlia profilaktyky ta likuvannia podahry: aktualnyi stan problemy. Svit medytsyny ta biolohii. 2017;4(62):197-203. [in Ukrainian].
24. Voronkov LH, Parashcheniuk LP, Protsenko HA. Sertseva nedostatnist ta podahra: klinichnyi vypadok. Ukrainskyi revmatolohichnyi zhurnal. 2019;3(77):82-85. [in Ukrainian].
25. Shuba NM, Voronova TD, Krylova AS. Rol hiperurykemii v rozvytku sertsevo-sudynnykh zakhvoriuvan. Ukrainskyi kardiolohichnyi zhurnal. 2019;26(3):78-92. DOI: 10.31928/1608-635X-2019.3.7892. [in Ukrainian].
26. Hohaieva OK. Osoblyvosti perioperatsiinoho periodu u patsiientiv z IKhS vysokoho ryzyku ta podahroiu v kardiokhirurhichnii praktytsi. Ukrainskyi revmatolohichnyi zhurnal. 2021;1(83):42-48. DOI: 10.32471/rheumatology. 2707-6970.83.15962. [in Ukrainian].
27. Smiian SI, Makhovska OIu. Nekontrolovana podahra yak mozhlyva prychyna komorbidnosti ta ryzyk tiazhkoho perebihu COVID-19. Ukrainskyi revmatolohichnyi zhurnal. 2023;1(87):1-8. DOI: 10.32471/ rheumatology.2707-6970.87.16902. [in Ukrainian].
28. Health-UA. Evoliutsiia dokazovykh pidkhodiv do vedennia patsiientiv iz podahroiu: shcho vazhlyvo znaty. Health-UA (Kardiolohiia/ Revmatolohiia); 2023. Dostupno: https://health-ua.com/cardiology/podagra-ta-giperurikemiia /73045-evolyutcya-dokazovih-pdhodv dovedennya-patcntv-zpodagroyusho-vazhlivo-znati. [in Ukrainian].

Publication of the article:

«Bulletin of problems biology and medicine», 2026 Issue 1, 180, 239-248 pages, index UDC 616.12-005.4:616-002.78:616.72-002

DOI:

10.29254/2077-4214-2026-1-180-239-248